Breaking News
U.S. Orders Intelligence Agencies to Increase Spying on Greenland
The Dark Side of Denmark's Welfare State
Anduril's Menace tech now preferred hardware for Palantir's Edge software
The most dangerous man in America isn't Trump--it's Alex Karp
Top Tech News
Cab-less truck glider leaps autonomously between road and rail
Can Tesla DOJO Chips Pass Nvidia GPUs?
Iron-fortified lumber could be a greener alternative to steel beams
One man, 856 venom hits, and the path to a universal snakebite cure
Dr. McCullough reveals cancer-fighting drug Big Pharma hopes you never hear about…
EXCLUSIVE: Raytheon Whistleblower Who Exposed The Neutrino Earthquake Weapon In Antarctica...
Doctors Say Injecting Gold Into Eyeballs Could Restore Lost Vision
Node without Consent
Dark Matter: An 86-lb, 800-hp EV motor by Koenigsegg
Spacetop puts a massive multi-window workspace in front of your eyes
DARPA Nucleic Technology Funded to Get Virus Response to 1-60 Days
The P3 teams are developing technologies to deliver antibodies using nucleic acid technology, and achieve sufficient serum concentrations of the antibodies for protection against the pathogen within three days after administration.
DARPA has programs for Pandemic Prevention Platform, Nucleic Acids On-Demand Worldwide (NOW), and PReemptive Expression of Protective Alleles and Response Elements (PREPARE) programs.
Nucleic Acids On-Demand Worldwide (NOW)
The goal of the NOW program is to develop a mobile medical countermeasure (MCM) manufacturing platform for use in stabilization and humanitarian operations to produce, formulate, and package hundreds of doses of nucleic acid therapeutics (DNA and/or RNA) in less than 24 hours. The developed platform should be a resilient, mobile, readily accessible nucleic acid MCM manufacturing capability that enables immediate threat response anywhere the military operates with minimal user intervention.